Therapeutic research and poisoning are different subjects
Cannabis enters pet health through two very different routes: research on particular cannabinoid preparations and accidental exposure to products intended for people. CBD has been studied in dogs, including for osteoarthritis, but that does not make ordinary cannabis a pet treatment. THC-containing products can cause adverse effects. The useful starting point is the animal, the condition and the exact exposure, rather than the general idea that a plant is natural.
What the osteoarthritis study measured
A 2018 randomized, blinded crossover study evaluated a hemp-derived CBD preparation in dogs with osteoarthritis; 16 dogs completed the trial. Pain and activity assessments improved during CBD treatment, while alkaline phosphatase, a blood enzyme, increased in some animals. The authors emphasized the specific preparation studied.
The result is interesting because it concerns a diagnosed painful joint condition and compares treatment with placebo. It is not evidence that every commercial pet oil has the same effect. Nor does an improvement in a pain questionnaire demonstrate that damaged cartilage has regenerated. Symptom relief, mobility and structural repair are different outcomes.
Why observation needs veterinary interpretation
Owners see an animal’s everyday behavior: getting up, climbing steps, playing or avoiding movement. These observations matter, but a quieter dog can reflect several things, including relief, sedation or illness. The interpretation changes when behavior is considered alongside examination, medical history and laboratory results.
The enzyme finding in the trial illustrates this point. A changed laboratory value needs clinical context; it cannot simply be labelled harmless because the animal appears comfortable, or equated automatically with proven liver injury. Monitoring is part of how treatment evidence becomes meaningful for an individual patient.
Accidental exposure has a different priority
The FDA lists lethargy, heavy drooling, vomiting, agitation, tremors and convulsions among possible adverse signs after cannabis ingestion in pets. An animal showing such changes after suspected exposure needs veterinary assessment. Immediate contact with a veterinarian or emergency veterinary hospital is appropriate; waiting for an online discussion can delay care.
The product matters as well as the plant. Packaging and ingredient information help the veterinarian understand what was swallowed. A human edible can contain other substances relevant to the animal’s condition, and a label mentioning CBD does not fully describe every possible exposure.
What this means for pet care in Spain
Spain’s Royal Decree 903/2025 concerns a human pharmaceutical framework; it is not a veterinary authorization for household cannabis use. Research conducted in dogs abroad provides scientific observations, while Spanish veterinary prescribing and product authorization remain separate regulatory questions.
The practical division is clear: promising veterinary research belongs within diagnosis, a defined preparation and professional follow-up. Accidental exposure belongs to timely veterinary care. Safe storage outside an animal’s reach addresses a preventable household risk without turning a research finding into a home treatment recipe. Dogs, cats and other species should not be treated as interchangeable patients.
Sources & further reading
General information, not individual legal or medical advice.